Skip to content

CDMO Services

iBio offers a full range of development and manufacturing services to move your projects from pre-clinical to market launch.  Our FastPharming® System shortens your development timelines and provides for seamless scale-up. Our Glycaneering Technology℠ affords greater control and can deliver increased product potency and quality.  We offer a range of recombinant products including monoclonal antibodies, antigens for subunit vaccine design, lysosomal enzymes, and many more.

Images of manufacturing facilities at iBio, a biopharmaceutical contract manufacturing company.
plant used in biopharma manufacturing processes


Why FastPharming?

FastPharming overcomes issues presented by mammalian expression systems:

Icon showing dials representing the faster biopharmaceutical manufacturing abilities of FastPharming by iBio

Greater speed-to-clinic by shaving months off traditional mammalian-cell development times

Icon representing upwards scaling, a manufacturing process which becomes easier with FastPharming

Vertical farming eliminates scaling issues moving to large bioreactors – just use more hydroponically-grown plants

Icon: checkmark on a shield, representing better control and performance of biopharma manufacturing with iBio's technology

Excellent glycosylation controls for better performance without freedom-to-operate issues

Icon: globe covered by leaves. represents reduced volume of single-use waste generated by the FastPharming manfuacturing process compared to mammalian cell culture production

Reduced volume of single-use disposables widely used in mammalian cell culture production

Icon: globe with a checkmark on a shield, indicating reduced risk of contamination when manufacturing with iBio's biotechnology

 Reduced contamination risk since mammalian viruses and prions can’t grow in plants

Icon: molecule or protein with expanding arrows around it, representing the ability to use Fastpharming for biopharmaceutical manufacturing to create a range of recombinant proteins and more

The system can express a wide range of recombinant proteins, including monoclonal antibodies, growth factors & cytokines, lysosomal enzymes, peptides, virus-like particles, and more

Explore FastPharming

Speed to Clinic

"Concept to drug Substance" can take as little as 3 months for FastPharming vs. 12 months or more for Mammalian Cell Culture
Graph: Clinical Product Manufacturing. 14 days for FastPharming vs. 40 days or more
  • Rapid Agrobacterium vector availability accelerates the timeline to Master Cell Bank (MCB) generation by as much as 10 months​
  • Bulk drug substance manufacturing timeline reduced because host plants can be ready on-demand thereby eliminating the seed train​
  • Rapid production timeline can support earlier preclinical safety and product stability studies which can potentially further reduce time to IND


Time to Drug Substance may vary and does not include product-specific process and assay development work. Mammalian cell culture timelines given above are for illustrative purposes only based upon competitive data from publicly available sources. Actual timelines may vary.

Technology Applications

The FastPharming Platform produces a variety of recombinant products including:

  • Biobetter and biosimilar antibodies
  • Antigens for subunit vaccine design
  • Virus-like particles (VLP)
  • Lysosomal enzymes
  • Blood factors, including cytokines, growth factors, and interleukins

See the 7 Reasons Why You Should Use Fastpharming to Grow Tomorrow's Biologics

Learn More